Global Cancer Vaccine Partnering Terms and Agreements 2010-2020

$3,495.00

The Global Cancer Vaccine Partnering Terms and Agreements 2010-2020 provides comprehensive understanding and unprecedented access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2020
Number of pages
200+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP22011

The Global Cancer Vaccine Partnering Terms and Agreements 2010-2020 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in cancer vaccine partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer vaccine partnering contract documents
  • Top cancer vaccine deals by value

 

This report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2010.

 

The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.

 

The report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 250 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Cancer Vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Vaccine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Cancer Vaccine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Vaccine dealmaking with a brief summary followed by a comprehensive listing of Cancer Vaccine deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Cancer Vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Vaccine partnering and dealmaking since 2010.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Vaccine technologies and products.

 

Key benefits

 

Global Cancer Vaccine Partnering Terms and Agreements 2010-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Cancer Vaccine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
  • Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
  • Identify most active Cancer Vaccine dealmakers since 2010
  • Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Cancer Vaccine Partnering Terms and Agreements 2010-2020 is intended to provide the reader with an in-depth understanding and access to Cancer Vaccine trends and structure of deals entered into by leading companies worldwide.

 

Cancer Vaccine Partnering Terms and Agreements includes:

 

  • Trends in Cancer Vaccine dealmaking in the biopharma industry since 2010
  • Analysis of Cancer Vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Cancer Vaccine deals
  • Access to Cancer Vaccine contract documents
  • Leading Cancer Vaccine deals by value since 2010
  • Most active Cancer Vaccine dealmakers since 2010

 

In Global Cancer Vaccine Partnering Terms and Agreements 2010-2020, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Cancer Vaccine Partnering Terms and Agreements 2010-2020 report provides comprehensive access to available deals and contract documents for over 250 Cancer Vaccine deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Cancer Vaccine Partnering Terms and Agreements 2010-2020 report provides the reader with the following key benefits:

 

  • In-depth understanding of Cancer Vaccine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
  • Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
  • Identify most active Cancer Vaccine dealmakers since 2010
  • Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Cancer Vaccine dealmaking

 

2.1. Introduction

2.2. Cancer Vaccine partnering over the years

2.3. Most active Cancer Vaccine dealmakers

2.4. Cancer Vaccine partnering by deal type

2.5. Cancer Vaccine partnering by therapy area

2.6. Deal terms for Cancer Vaccine partnering

2.6.1 Cancer Vaccine partnering headline values

2.6.2 Cancer Vaccine deal upfront payments

2.6.3 Cancer Vaccine deal milestone payments

2.6.4 Cancer Vaccine royalty rates

 

Chapter 3 – Leading Cancer Vaccine deals

 

3.1. Introduction

3.2. Top Cancer Vaccine deals by value

 

Chapter 4 – Most active Cancer Vaccine dealmakers

 

4.1. Introduction

4.2. Most active Cancer Vaccine dealmakers

4.3. Most active Cancer Vaccine partnering company profiles

 

Chapter 5 – Cancer Vaccine contracts dealmaking directory

 

5.1. Introduction

5.2. Cancer Vaccine contracts dealmaking directory

 

Chapter 6 – Cancer Vaccine dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Cancer Vaccine deals by company A-Z

 

Appendix 2 – Cancer Vaccine deals by stage of development

 

Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

Formulation

 

Appendix 3 – Cancer Vaccine deals by deal type

 

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation        

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

 

Appendix 4 – Cancer Vaccine deals by therapy area

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Cancer Vaccine partnering since 2010

Figure 2: Active Cancer Vaccine dealmaking activity since 2010

Figure 3: Cancer Vaccine partnering by deal type since 2010

Figure 4: Cancer Vaccine partnering by disease type since 2010

Figure 5: Cancer Vaccine deals with a headline value

Figure 6: Cancer Vaccine deals with an upfront value

Figure 7: Cancer Vaccine deals with a milestone value

Figure 8: Cancer Vaccine deals with a royalty rate value

Figure 9: Top Cancer Vaccine deals by value since 2010

Figure 10: Most active Cancer Vaccine dealmakers since 2010

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2A, A*STAR Bioprocessing Technology Institute, Accelovance, Adamis Pharmaceuticals, AdnaGen, Aduro BioTech, Advanced BioScience Laboratories, Advaxis, AEterna Zentaris, Affitech, Agenus Bio, Agilent Technologies, Aldevron, Alliance for Biosecurity, Alnylam Pharmaceuticals, Amaran Biotechnology, Amarna Therapeutics, American Dental Association, Analytical Bio-Chemistry Laboratories, AnGes MG, Anixa Biosciences, Annias Immunotherapeutics, Antigen Express, Antitope, Apceth, Ariad Pharmaceuticals, Aslan Pharma, Asterias Biotherapeutics, AstraZeneca, Astrimmune, Aura Biosciences, Averion, AV Therapeutics, Batu Biologics, Bavarian Nordic, Bayer, Bayer Innovation, Baylor College, Baylor College of Medicine, Baylor Institute for Immunology Research, Baylor Research Institute, Beijing Genomics Institute (BGI), Bellicum Pharmaceuticals, Beth Israel Deaconess Medical Center, BGI, BIND Biosciences, BinnoPharm, BioAlliance Pharma, BioClones, BioNTech, Biooutsource, BioSante Pharmaceuticals, Biotech Synergy, Biothera, BioVaxys, BioVest, Bluebird Bio, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Bpifrance, Bristol-Myers Squibb, Broad Institute, Broadvector, Brown University, Button Capital, Caladrius Biosciences, California Institute of Technology, Cancer Immunotherapy Trials Network, Cancer Prevention and Research Institute of Texas, Cancer Research Institute, Cancer Research Technology, Cancer Research UK, Cancer Research Wales, Cardiff University, Catalan Institute of Nanotechnology (ICN), Catherex, Celldex Therapeutics, Cellular Biomedicine, Center for Biomarker Research in Medicine, Centogene, ChemRar High-Tech Center, Chugai Pharmaceutical, CiMaas, City of Hope Comprehensive Cancer Center, Cleveland BioLabs, Cleveland Clinic, Clinigen, Clinipace Worldwide, Cobra Biologics, Cofactor Genomics, Colby Pharmaceuticals, Cristal Therapeutics, CSIRO, CureLab Oncology, CureVac, Cyplasin Biomedical, CYTLIMIC, Daiichi Sankyo, Dainippon Sumitomo Pharma, Dalton Pharma Services, Dana-Farber Cancer Institute, DanDrit Biotech, Davospharma, DCPrime, Delta-Vir, Dendreon, Department of Defense, Diosynth, DNAtrix, DxS, Eli Lilly, EMD Serono, Emory University, Epimmune, EpiThany, Ervaxx, eTheRNA immunotherapies, Etubics, European Union, Evvivax, Exiqon, Federal Ministry of Education and Research (BMBF), Flow Pharma, Formatech, Forska and Vax, Fraunhofer Institute for Cell Therapy and Immunology, Fred Hutchinson Cancer Research Center, G-Con, Galena Biopharma, Genentech, Generex Biotechnology, Genetic Immunity, Genexine, Genocea Biosciences, GenoLac, Genomic Expression, GenVec, Georgetown University, Georgia Health Sciences University, GeoVax, German Cancer Research Center, GISCAD Foundation, GlaxoSmithKline, Government of Rwanda, Gritstone Oncology, Hanmi Pharmaceutical, Harvard University, Heat Biologics, Hefei Sageland Biotechnology, Helmholtz Zentrum Munchen, HemaCare, HemispheRx Biopharma, Henry M. Jackson Foundation, Hoffmann La Roche, Hokkaido University, Hookipa Pharma, Human Vaccines Project, iBio, Icahn School of Medicine at Mount Sinai, Ichor Medical Systems, IGNITE Immunotherapy, Immatics Biotechnologies, Immune Design, ImmuneRegen BioSciences, Immunicum, ImmunID Technologies, ImmunoCellular Therapeutics, Immunomic, ImmunoPhotonics, Immunovaccine, Immunovo, Inovio Pharmaceuticals, InProTher, Intensity Therapeutics, InteRNA Technologies, IOVaxis Therapeutics, IRX Therapeutics, Jaiva Technologies, Janssen Pharmaceuticals, Jantibody Therapeutics, Japan Vaccine, Jennerex, John Hopkins University School of Medicines, John P. Hussman Foundation, Johns Hopkins University, Johnson & Johnson Innovation, JSC Binnopharm, JSC Pharmadis, Juvaris BioTherapeutics, KAEL-GemVax, KellBenx, Kindred Bio, Leukaemia & Lymphoma Research, LG Life Sciences, Ligand Pharmaceuticals, Lineage Cell Therapeutics, LineaRx, London Genetics, Ludwig Institute for Cancer Research, Lumos Pharma, Lung Cancer Research Foundation, LUNGevity Foundation, MabVax Therapeutics, Madison Vaccines, MannKind Biopharmaceuticals, Massachusetts General Hospital, Mayo Clinic, MD Anderson Cancer Center, MDxHealth, Medac, MediGene, MedImmune, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Methodist Hospital Research Institute, Ministry of Industry and Trade of the Russian Federation, Moderna Therapeutics, Morphogenesis, MorphoSys, Morphotek, Mymetics, Nanobiotix, NantBioScience, NantKwest, National Cancer Institute, National Cancer Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, National Research Council Canada, National Surgical Adjuvant Breast and Bowel Project, NEC, Neon Therapeutics, Netherlands Cancer Institute, NeuClone, Neumedicines, NewVac, Northwest Biotherapeutics, Norwegian Cancer Society, Norwegian Research Council, Nottingham City Council, Novartis, Novartis Animal Health, NYU Langone Medical Center, Ohio State University, Omnimmune, Omnis Pharmaceuticals, OncoImmunity, OncoPep, OncoQR, OncoSec Medical, Oncotherapy Science, Oncothyreon, Oncovir, Ono Pharmaceutical, OSE Pharma (Orphan Synergy Europe Pharma), Oxford BioMedica, Oxford Immunotec, Panacea Pharmaceuticals, Panacela Labs, PDC*line Pharma, Pepscan Therapeutics, Pfenex, Pfizer, PharmaCell, Pharmanet/i3, PharmaNet Development Group, PharmaPraxis, PlantForm, PPD, PRIMA BioMed, Profectus Biosciences, Progenitor Cell Therapy, Prometheus Laboratories, Prostate Cancer Foundation (PCF), Provecs Medical, PsiOxus Therapeutics, Pulmotec, PX Biosolutions, Qiagen, Radboud University Nijmegen Medical Centre, Radiation Control Technologies, Radient Pharmaceuticals, RareCyte, Regen BioPharma, Regeneron Pharmaceuticals, Research Institute of the Hospital Universitari Vall d'Hebron, Riyadh Pharma, Roche, Rosetta Genomics, RXi Pharmaceuticals, San Martino Hospital, Sanofi, Scancell, Selecta Biosciences, Selexis, Sellas Clinicals Holding, Seres Therapeutics, Serum Institute of India, SFJ Pharmaceuticals, Shenzhen BioScien Pharmaceuticals, SillaJen, Sirion Biotech, Skolkovo Foundation, SOTIO, Spectrum Pharmaceuticals, Spotlight Innovation, SRI International, Stanford University, Stellar Biotechnologies, Stellar Pharmaceuticals, Stemline Therapeutics, Susan G. Komen for the Cure, Takis Biotech, TapImmune, Targovax, Tasly Pharmaceuticals, Telormedix, Teva Pharmaceutical Industries, The International AIDS Vaccine Initiative, The Parker Institute For Cancer Immunotherapy, Theravectys, The Regents of the University of California, Thomas Jefferson University, ToleRx, Torrey Pines Institute for Molecular Studies, Transgene, Transgene Tasly Biopharmaceutical, Transgenomic, Treos Bio, TYG oncology, UbiVac, UK Government, University Medical Center Groningen, University of Alabama at Birmingham, University of Basel, University of California, Davis, University of California, San Diego, University of Chicago, University of Copenhagen, University of Greifswald, University of Massachusetts Medical School, University of Miami, University of North Carolina, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Queensland, University of Rostock, University of Rouen, University of South Florida, University of Texas at El Paso, University of Turin, University of Western Ontario, Vaccibody, Vaccine and Gene Therapy Institute of Florida (VGTI-FL), Vaccinogen, Valo Therapeutics, Vanderbilt University, Vaxeal, Vaxil BioTherapeutics, Vaximm, VBI Vaccines, Vedantra Pharmaceuticals, VGX International, Vinnova, ViroMed, Vivalis, VLP Therapeutics, VLST Corporation, VU University Amsterdam, Vyriad, Washington University in St Louis, Weill Cornell Medical College, Western Oncolytics, Wilex, Wistar Institute, WuXi Biologics, Wyss Institute, Xencor, Y-mAbs Therapeutics, Yale University, Yamaguchi University

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.